IRMD on Nasdaq
IRADIMED CORP
American surgical and medical instruments and apparatus company.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Delcath Systems, Inc., TELA Bio, Inc. or Pulmonx Corp, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
76.7%Gross margin3
31.2%Operating margin3
26.8%Net margin3
14.4%Revenue growth, 20253
23.8%Return on equity3
$17.2MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 84% of the revenue IRADIMED CORP broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $60.6M | $70.6M |
| Outside the United States | $12.6M | $13.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue23¢$19.5M
- Research and development4¢$3.0M
- Other costs39¢$33.0M
- Income tax7¢$5.9M
- Profit27¢$22.5M
Out of $83.8M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Capital spending31¢$7.8M
- Dividends paid60¢$15.0M
- Kept or used elsewhere9¢$2.1M
Out of $24.9M of cash from operations.3
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $83.8M | $73.2M |
| Cost of revenue | $19.5M | $16.9M |
| Gross profit | $64.3M | $56.4M |
| General and administrative | $17.8M | $15.9M |
| Sales and marketing | $17.4M | $15.6M |
| Research and development | $3.0M | $2.8M |
| Total operating expenses | $38.2M | $34.4M |
| Income from operations | $26.1M | $22.0M |
| Other income, net | $2.2M | $2.3M |
| Income before provision for income taxes | $28.4M | $24.3M |
| Provision for income tax expense | $5.9M | $5.0M |
| Net income | $22.5M | $19.2M |
| Basic (in dollars per share) | $1.77 | $1.52 |
| Diluted (in dollars per share) | $1.75 | $1.50 |
| Basic (in shares) | 12.7M shares | 12.7M shares |
| Diluted (in shares) | 12.9M shares | 12.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $51.2M | $52.2M | |
| Accounts receivable, net of allowance for credit losses of $191 as of December 31, 2025, and $274 as of December 31, 2024 | $13.7M | $10.6M | |
| Inventory, net | $11.6M | $10.4M | |
| Prepaid expenses and other current assets | $4.8M | $2.0M | |
| Total current assets | $81.2M | $75.2M | |
| Property and equipment, net | $23.9M | $16.8M | |
| Intangible assets, net | $3.4M | $3.1M | |
| Deferred tax asset, net | $94.0K | $2.8M | |
| Other assets | $239.0K | $354.0K | |
| Total assets | $108.8M | $98.3M | |
| Accounts payable | $1.8M | $1.9M | |
| Accrued payroll and benefits | $3.2M | $3.8M | |
| Warranty reserve | $144.0K | $118.0K | |
| Deferred revenue | $2.9M | $2.3M | |
| Other current liabilities | $313.0K | $466.0K | |
| Accrued income taxes | $1.8M | ||
| Total current liabilities | $10.2M | $8.5M | |
| Deferred revenue, non-current | $4.0M | $3.0M | |
| Operating lease liabilities, non-current | $2.0K | ||
| Total liabilities | $14.2M | $11.5M | |
| Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,781,774 shares issued and outstanding as of December 31, 2025, and 12,709,860 shares issued and outstanding as of December 31, 2024 | $1.0K | $1.0K | |
| Additional paid-in capital | $30.4M | $30.0M | |
| Retained earnings | $64.2M | $56.8M | |
| Total stockholders' equity | $94.6M | $86.8M | $71.4M |
| Total liabilities and stockholders' equity | $108.8M | $98.3M | |
| Allowance for credit losses | $191.0K | $274.0K | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 31.5M shares | 31.5M shares | |
| Common stock, shares issued | 12.8M shares | 12.7M shares | |
| Common stock, shares outstanding | 12.8M shares | 12.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $51.2M | $52.2M | |
| Accounts receivable, net of allowance for credit losses of $191 as of December 31, 2025, and $274 as of December 31, 2024 | $13.7M | $10.6M | |
| Inventory, net | $11.6M | $10.4M | |
| Prepaid expenses and other current assets | $4.8M | $2.0M | |
| Total current assets | $81.2M | $75.2M | |
| Property and equipment, net | $23.9M | $16.8M | |
| Intangible assets, net | $3.4M | $3.1M | |
| Deferred tax asset, net | $94.0K | $2.8M | |
| Other assets | $239.0K | $354.0K | |
| Total assets | $108.8M | $98.3M | |
| Accounts payable | $1.8M | $1.9M | |
| Accrued payroll and benefits | $3.2M | $3.8M | |
| Warranty reserve | $144.0K | $118.0K | |
| Deferred revenue | $2.9M | $2.3M | |
| Other current liabilities | $313.0K | $466.0K | |
| Accrued income taxes | $1.8M | ||
| Total current liabilities | $10.2M | $8.5M | |
| Deferred revenue, non-current | $4.0M | $3.0M | |
| Operating lease liabilities, non-current | $2.0K | ||
| Total liabilities | $14.2M | $11.5M | |
| Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,781,774 shares issued and outstanding as of December 31, 2025, and 12,709,860 shares issued and outstanding as of December 31, 2024 | $1.0K | $1.0K | |
| Additional paid-in capital | $30.4M | $30.0M | |
| Retained earnings | $64.2M | $56.8M | |
| Total stockholders' equity | $94.6M | $86.8M | $71.4M |
| Total liabilities and stockholders' equity | $108.8M | $98.3M | |
| Allowance for credit losses | $191.0K | $274.0K | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 31.5M shares | 31.5M shares | |
| Common stock, shares issued | 12.8M shares | 12.7M shares | |
| Common stock, shares outstanding | 12.8M shares | 12.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | $22.5M | $19.2M |
| Allowance for credit losses | -$84.0K | -$95.0K |
| Provision for excess and obsolete inventory | $47.0K | $88.0K |
| Depreciation & amortization | $1.2M | $818.0K |
| Loss on disposal of property and equipment | $37.0K | $4.0K |
| Stock-based compensation | $2.9M | $2.5M |
| Deferred income taxes, net | $2.7M | -$698.0K |
| Accounts receivable | -$3.0M | $1.8M |
| Inventory | -$1.4M | $3.1M |
| Prepaid income taxes | -$2.6M | -$786.0K |
| Prepaid expenses and other current assets | -$132.0K | -$320.0K |
| Other assets | -$40.0K | -$17.0K |
| Accounts payable | -$76.0K | -$862.0K |
| Accrued payroll and benefits | -$554.0K | $997.0K |
| Other accrued taxes | $150.0K | $60.0K |
| Warranty reserve | $26.0K | $1.0K |
| Deferred revenue | $1.6M | -$111.0K |
| Other current liabilities | -$150.0K | -$100.0K |
| Accrued income taxes | $1.8M | |
| Net cash provided by operating activities | $24.9M | $25.6M |
| Purchases of property and equipment | -$7.8M | -$8.0M |
| Capitalized intangible assets | -$656.0K | -$812.0K |
| Net cash used in investing activities | -$8.4M | -$8.8M |
| Dividends paid | -$15.0M | -$13.7M |
| Proceeds from exercises of stock options | $29.0K | |
| Taxes paid related to the net share settlement of equity awards | -$2.6M | -$688.0K |
| Net cash used in financing activities | -$17.6M | -$14.3M |
| Net (decrease) increase in cash and cash equivalents | -$1.1M | $2.5M |
| Cash paid for income taxes | $3.9M | $6.5M |
| ROU asset and liability adjustment | $1.5M | |
| Operating and short-term lease payments recorded within cash flow provided by operating activities | $489.0K | $817.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led IRADIMED CORP, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerRoger E. Susi Jul 15, 2014 to now11
- ChairRoger E. Susi Nov 16, 2016 to now12
- PresidentRoger E. Susi Jul 15, 2014 to now11
- Chief financial officerJohn Glenn Jun 22, 2022 to now13
- Chief operating officerJohn K. McCreery Apr 11, 2017 to Jan 8, 202014
Board members and other officers (14)
- Chief Commercial OfficerJeff Chiprin Dec 6, 2024 to now15
- Chief Exec Officer & DirectorLeslie L. McDonnell Aug 23, 2019 to Dec 10, 201916
- Chief Technology Offr, ChmnRoger E. Susi Sep 10, 2019 to Sep 10, 201917
- Exec VP, Worldwide Sales-MktgBrent Johnson Jul 15, 2014 to Apr 14, 202018
- VP of Reg & Qual AssuranceFrancis X. Casey Jul 15, 2014 to Jan 3, 202019
- ControllerLouis S. Waldman Jul 15, 2014 to Feb 14, 202020
- VP of ManufacturingSteven M. Nardi Jul 15, 2014 to Feb 24, 202021
- Board memberHilda Frederique Scharen-Guivel Oct 13, 2022 to now22
- Board memberLeslie L. McDonnell Aug 23, 2019 to Aug 28, 201916
- Board memberAnthony Vuoto Mar 30, 2016 to Dec 13, 202423
- Board memberJames B. Hawkins Jul 15, 2014 to now24
- Board memberMonty K. Allen Jul 15, 2014 to now25
- Board memberRoger E. Susi Jul 15, 2014 to Sep 10, 201911
- Board memberSerge Novovich Jul 15, 2014 to Feb 22, 201626
Timeline
- Jul 15, 2014New chief executive Roger E. Susi becomes CEO11
Filings
317 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 45 major events, 193 insider forms, 17 large holders, 41 other. The latest 20:
- Sep 25, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 3, 2026144 EDGAR
- Aug 18, 20268-K/A EDGAR
- Jul 31, 202610-Q EDGAR
- Jul 31, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G EDGAR
- Jun 24, 20268-K EDGAR
- Jun 23, 20264 EDGAR
- Jun 4, 20264 EDGAR
- Jun 4, 2026144 EDGAR
- Jun 2, 20264 EDGAR
- May 28, 20264 EDGAR
- May 20, 20264 EDGAR
- May 14, 2026SCHEDULE 13G/A EDGAR
- May 13, 20264 EDGAR
- May 6, 20264 EDGAR
- May 1, 202610-Q EDGAR
- May 1, 20268-K EDGAR
- Apr 30, 2026ARS EDGAR
The 317 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 17 such filings since October 2021, the latest 10:
- Jul 28, 2026SCHEDULE 13G
- May 14, 2026SCHEDULE 13G/A
- Feb 10, 2026SCHEDULE 13G/A
- Feb 13, 2025SCHEDULE 13G
- Nov 14, 2024SC 13G/A
- Nov 8, 2024SC 13G
- Oct 22, 2024SC 13G
- Feb 13, 2024SC 13G/A
- Feb 12, 2024SC 13G/A
- Feb 9, 2024SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARIRADIMED CORP filings on SEC EDGAR
- 2SEC EDGARIRADIMED CORP filings on SEC EDGAR
- 3SEC EDGARIRADIMED CORP 10-K for fiscal 2025
- 4SEC EDGARIRADIMED CORP 10-K for fiscal 2019
- 5SEC EDGARIRADIMED CORP 10-K for fiscal 2021
- 6SEC EDGARIRADIMED CORP 10-K for fiscal 2022
- 7SEC EDGARIRADIMED CORP 10-K for fiscal 2023
- 8SEC EDGARIRADIMED CORP 10-Q for fiscal 2026
- 9SEC EDGARIRADIMED CORP 10-Q for fiscal 2026
- 10SEC EDGARIRADIMED CORP 10-K for fiscal 2019
- 11
- 12SEC EDGARRoger E. Susi, Chair
- 13SEC EDGARJohn Glenn, Chief financial officer
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARLouis S. Waldman, Controller
- 21SEC EDGARSteven M. Nardi, VP of Manufacturing
- 22
- 23SEC EDGARAnthony Vuoto, Board member
- 24SEC EDGARJames B. Hawkins, Board member
- 25SEC EDGARMonty K. Allen, Board member
- 26SEC EDGARSerge Novovich, Board member